Crispr Stock Forecast Zacks

This compares to loss of $1.32 per share a. The zacks consensus estimate has increased $3.67 to $4.81.

Ocurufpcvdwugm

This has resulted in an earnings esp of 0%.

Crispr stock forecast zacks. Crsp, a #3 (hold) stock, was added to the focus list on may 18, 2021 at $109.22 per share. The zacks consensus estimate has increased $3.67 to $4.81. Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2021.

Crsp boasts an average earnings surprise of 21.6. The lowest sales estimate is $500,000.00 and the highest is. The stock is currently a #3 (hold) on the zacks rank.

Since then, shares have increased 14.47% to $125.02. For fiscal 2021, six analysts revised their earnings estimate upwards in the last 60 days, and the zacks consensus estimate has increased $4.22 to $4.88. For crispr therapeutics ag, the most accurate estimate is lower than the zacks consensus estimate, suggesting that analysts have recently become bearish on the company's earnings prospects.

In 1978, our founder discovered the power of. See the report's 7 new picks today. Crsp boasts an average earnings surprise of 21.6%.

The zacks consensus estimate has. The stock is currently a #3 (hold) on the zacks rank. Each stock is a zacks rank #1 strong buy.

You can see the complete list of today’s zacks #1 rank (strong buy) stocks here. For crispr therapeutics ag, the most accurate estimate is the same as the zacks consensus estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. On average, 8 wall street analysts forecast crsp's earnings for 2021 to be $368,094,697, with the lowest crsp earnings forecast at $334,422,833, and the highest crsp earnings forecast at $407,888,718.

Since being added to the focus list on may 18, 2021 at $109.22 per share, shares of crsp have increased 7.51% to $117.42. The stock is currently a #3 (hold) on the zacks rank. There are few to no technical positive signals at the moment.

On the other hand, the stock currently carries a zacks rank of #4. 's earnings in 2021 is $411,870,000. Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2021.

Zacks zacks is the leading investment research firm focusing on stock research, analysis and recommendations. Additionally, crsp's earnings are expected to grow 190.9% for the current fiscal year. Crispr therapeutics ag (crsp) came out with a quarterly loss of $1.67 per share versus the zacks consensus estimate of a loss of $1.69.

Six analysts have provided estimates for crispr therapeutics' earnings. Wall street analysts expect crispr therapeutics ag (nasdaq:crsp) to announce $5.39 million in sales for the current quarter, zacks reports. Crispr therapeutics ag (crsp) came out with a quarterly loss of $1.67 per share versus the zacks consensus estimate of a.

Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2021. On the other hand, the stock currently carries a zacks rank of #4. View crispr therapeutics ag crsp investment & stock information.